EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

A Phase I, Double-blind, Randomized, Placebo-controlled, Single Dose-escalation Study to Evaluate the Tolerability, and Safety of Cytisinicline in Adult Smokers

Cindy Jacobs, Marlene Fonseca, Nancy A Rigotti, Neal Benowitz iD, Anthony Clarke, Dan Cain

Nicotine & Tobacco Research · 22.03.2023 · 25 (4) · 814-820

DOI: 10.1093/ntr/ntac233 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nicotine & Tobacco Research, online erschienen am 05.10.2022. Verfasst von Cindy Jacobs und 5 weiteren Autor:innen. Beteiligte Einrichtung: Achieve Life Sciences Inc., 22722 29th Dr SE Suite 100, Bothell WA 98021, USA. Hauptthemen laut MEDLINE: Smokers. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Achieve Life Sciences, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cytisinicline is a nicotinic acetylcholine receptor partial agonist marketed historically as oral tablets in Central and Eastern Europe as an aid to smoking cessation. Dosing and scheduled regimen for cytisinicline treatment is currently being redeveloped for market approval in the United States and elsewhere. Aims and Methods A phase 1, double-blind, randomized, placebo-controlled, single-ascending dose clinical trial was conducted under fasting conditions in healthy adults who were current daily (>10 cigarettes) smokers. Safety parameters for the identification of a maximum tolerated dose (MTD) and limited supportive pharmacokinetic assessments were evaluated. Ascending single oral doses of cytisinicline or placebo were administered to 9 cohorts, each comprised of eight unique participants (randomization: 6 cytisinicline; 2 placebo). Dose escalation to the next cohort was dependent upon the safety review of preceding cohorts. Dose levels tested were 6, 9, 12, 15, 18, 21, 24, 27, and 30 mg. Treatment-emergent adverse events (TEAEs) and clinically relevant changes in laboratory blood tests, vital signs, and 12-lead electrocardiograms were evaluated.

Results

Seventy-two participants completed the study (54 cytisinicline; 18 placebo). Nausea was the most common TEAE (10 participants [19%]). The MTD was defined as cytisinicline 30 mg based on gastrointestinal symptoms, predominantly vomiting (2 of 6 subjects, 33%). Maximum plasma concentration (observed Cmax) values appeared to plateau at higher dose levels (beyond 24 mg).

Conclusions

Single cytisinicline doses up to 30 mg were well tolerated and raised no new safety concerns in fasting adult smokers. An increased frequency of gastrointestinal symptoms defined the MTD at 30 mg.

Implications

The cytisinicline therapeutic dose being evaluated in phase 3 clinical trials is 3 mg, which is a 10-fold lower dose than the 30 mg MTD level for cytisinicline, resulting in an excellent safety margin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SmokersAdultHumansEurope, EasternDouble-Blind MethodDose-Response Relationship, Drug

Autor:innen und Institutionen

  • Achieve Life Sciences Inc., 22722 29th Dr SE Suite 100, Bothell WA 98021, USA.
  • BlueClinical Phase I Unit, Porto, Portugal.
  • Tobacco Research and Treatment Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Center for Tobacco Control Research and Education, University of California San Francisco, San Francisco, CA, USA.

ORCID-Profile: Neal Benowitz

Förderung

  • Achieve Life Sciences, Inc

Zitieren

APA

Jacobs, C., Fonseca, M., Rigotti, N. A., Benowitz, N., Clarke, A., & Cain, D. (2023). A Phase I, Double-blind, Randomized, Placebo-controlled, Single Dose-escalation Study to Evaluate the Tolerability, and Safety of Cytisinicline in Adult Smokers. Nicotine & Tobacco Research, 25(4), 814-820. https://doi.org/10.1093/ntr/ntac233

Vancouver

Jacobs C, Fonseca M, Rigotti NA, Benowitz N, Clarke A, Cain D. A Phase I, Double-blind, Randomized, Placebo-controlled, Single Dose-escalation Study to Evaluate the Tolerability, and Safety of Cytisinicline in Adult Smokers. Nicotine & Tobacco Research. 2023;25(4):814-820. doi:10.1093/ntr/ntac233

BibTeX
@article{Jacobs2023,
  author = {Jacobs, Cindy and Fonseca, Marlene and Rigotti, Nancy A and Benowitz, Neal and Clarke, Anthony and Cain, Dan},
  title = {A Phase I, Double-blind, Randomized, Placebo-controlled, Single Dose-escalation Study to Evaluate the Tolerability, and Safety of Cytisinicline in Adult Smokers},
  journal = {Nicotine & Tobacco Research},
  year = {2023},
  volume = {25},
  number = {4},
  pages = {814--820},
  doi = {10.1093/ntr/ntac233}
}
Kostenlos starten →